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Preterm birth is a major public health concern impacting one in eight 
babies born in the U.S.A.  Although a precise cause for preterm birth cannot be 
established in most cases, one of the most promising predictors of preterm birth 
is inflammation of the extra-placental gestational membranes.  Gestational 
membrane production of pro-inflammatory cytokines has been shown to initiate 
term parturition pathways and is thought to play a role in preterm parturition as 
well. 
Pregnant woman are exposed to a wide array of environmental pollutants, 
but few have been investigated epidemiologically for association with preterm 
birth and none have been satisfactorily investigated mechanistically.  
Polybrominated diphenyl ethers (PBDEs) are emerging toxicants of concern that 
have received limited attention regarding potential risks to human health and 
birth outcomes.  Preliminary research suggests that PBDEs may stimulate the 
gestational membranes to secrete pro-inflammatory cytokines in vitro.   
This dissertation tests the hypothesis that polybrominated diphenyl ethers 
bioaccumulate in the human gestational compartment and stimulate cytokine 
secretion from human gestational membranes.  Total PBDE levels were 
measured in the human gestational membranes and found at levels of 17.4±3.9 






pg/ml fluid (404±126 ng/g lipid).  Congener-specific profiles for the 21 congeners 
measured identified only tri- through hexa-BDEs in gestational membranes.  In 
contrast, tri- through deca-BDE congeners were found in amniotic fluid.  To 
assess stimulation of inflammatory responses in human gestational membranes, 
two tissue culture systems were compared for cytokine release into the culture 
medium: a biopsy punch explant culture system and a transwell mounted explant 
culture system.  Although lipopolysacharide stimulated a robust increase of 
interleukins-1β, 6, 8, 10 and tumor necrosis factor-α in both systems, with an 
amplified release of interleukins-6, 8 and 10 in the punch culture system, no 
increase in cytokine release was observed in response to PBDE stimulation.  
This is the first report of PBDE accumulation in the human gestational 
membranes, providing a basis for future investigations of toxic action in this 
tissue and the first to suggest amniotic fluid as a significant route of PBDE 



















Preterm birth - a public health crisis. 
The scientific community’s understanding of the mechanisms that regulate 
the timing of birth remains limited.  Since 1981, the rate of preterm births, defined 
as delivery at less than 37 weeks completed gestation, has increased over 30% 
and now accounts for 12.7% of live births in the U.S.1  The single largest cause 
of perinatal mortality and morbidity, preterm birth is associated with over one-
third of infant deaths2 and can lead to a host of developmental impairments 
including respiratory, gastrointestinal and neural abnormalities.3  Average first-
year medical costs are 10 times greater for preterm than for term infants, 
contributing to economic burdens in excess of $26.2 billion per year.4  The 
emotional and societal burdens associated with the premature birth of one in 
every eight babies cannot be estimated.   
Spontaneous preterm births due to preterm premature labor or preterm 
premature rupture of membranes (PPROM) account for 65-75% of all preterm 
births.5  Labor following PPROM accounts for 25-30% of preterm births.5, 6  
PPROM is defined as the spontaneous rupture of the gestational membranes at 
less than 37 weeks gestation at least 1 hour prior to the onset of uterine 
contractions.  Neither the pathogenesis of preterm delivery nor that of PPROM 
has been well elucidated.  It has been suggested that these conditions may arise 
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due to the untimely idiopathic activation of normal labor processes, potentially as 
the result of pathological insults.5 
In most cases a precise cause for preterm birth cannot be established.  
Therefore, associated risk factors have been sought to explain preterm labor and 
PPROM.   Many social, environmental, and physical factors have been 
associated with increased risk of adverse birth outcomes.  Previous preterm 
delivery, African-American ethnicity, multi-fetal pregnancies, conception through 
in vitro fertilization, low socioeconomic  or educational status, inadequate 
nutrition, low and high maternal ages, cigarette smoking and bacterial infection 
have all been linked to preterm birth.5  Of these, bacterial infection shows the 
strongest potential for direct mechanistic linkage for singleton births through the 
activation of pro-inflammatory cascades.  Although infections as far reaching as 
periodontal disease have shown positive correlations with preterm birth,7 it is 
infections of the extra-placental gestational membranes that provide the best 
clues to the etiology of preterm birth and PPROM. 
As suggested by the trend of increasing preterm birth rates, current clinical 
interventions have proven relatively unsuccessful.4  Although antibiotic treatment 
can prolong pregnancy for women experiencing PPROM at 34 or fewer weeks 
gestation,8 many studies have shown that prophylactic administration of 
antibiotics does not reduce the risk of preterm birth.9, 10  This leads to the 
conclusion that preterm birth does not fit the traditional “1 cause / 1 disease” 
paradigm.  Instead, preterm birth should be considered a syndrome with many 
interrelated risk factors.   
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Inflammation and the role of cytokines in parturition.  
Parturition is marked by three major changes within the gestational 
compartment: 1) sustained phasic contraction of the uterine muscle, 2) 
remodeling of the cervix, and 3) rupture of the extra-placental gestational 
membranes.   
The gestational membranes are made up of three distinct layers: the 
amnion, the chorion and the decidua.  The amnion is of fetal origin and faces the 
inner fetal compartment.  The chorion, also of fetal origin, is found between the 
amnion and the decidua.  The decidua is the maternal tissue derived from the 
endometrium and connecting the chorion to the uterine wall.  The amnion and 
chorion are separated by a dense collagen layer that provides structural integrity 
to the membranes while maintaining elasticity.  The chorion and decidua do not 
have a defined boundary and are often referred to as the choriodecidua.  These 
gestational membranes surround the fetus and contain the amniotic fluid during 
pregnancy, creating a barrier between mother and fetus.  The anatomy of the 
pregnant uterus is further detailed in Figure 1.1. 
Normal term parturition is an inflammatory-like process mediated by 
endogenous cytokines and prostaglandins.  Cytokines are small (8-30 kDa) 
hydrophilic signaling peptides and glycoproteins used in autocrine, paracrine and 
endocrine signaling throughout the body.  In response to a pro-inflammatory 
stimulus, cytokines play an important role in T-cell and macrophage recruitment 
as well as activation of the innate and adaptive immune responses.11-13  The 
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onset of labor is marked by a strong induction of cytokine secretion,14-17 including 
secretion by each of the three layers of the extra-placental gestational 
membranes,14, 18-22 leading to the activation of prostaglandins23 and matrix 
metalloproteinases.24   
The up-regulation of inflammatory genes14, 15 and subsequent release of 
pro-inflammatory cytokines17, 25-28 have been associated with parturition in many 
studies.  Furthermore, increased levels of the pro-inflammatory cytokines 
interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNFα) 
have each been associated with preterm birth.29-32 
Clinical indications of bacterial infection and inflammation within the 
human gestational membranes suggest that 25-40% of preterm births may be 
attributable to bacterial causes.33  Ascending microbes from the vaginal 
microflora are thought to infiltrate the uterine cavity via the cervix.  This results in 
a progressive infection beginning in the decidua (deciduitis), advancing through 
the chorion and amnion (chorioamnionitis) and finally entering the amniotic 
fluid.34  These bacteria stimulate pro-inflammatory cytokines which in turn recruit 
neutrophils, macrophages and lymphocytes to the gestational membranes.  
Traditionally, pathologic examination has been the gold standard for diagnosis of 
inflammation, but more recently it has been suggested that subclinical cases of 
inflammation are common and may play a role in preterm birth.34-36  This is 
supported by molecular evidence that women with negative diagnoses of clinical 
infection but positive polymerase chain reaction screens for bacteria in the 
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amniotic fluid have similar rates of preterm birth as women with positive 
diagnoses of clinical infection.37 
 
Non-infectious stimuli in preterm birth and pro-inflammatory cytokine induction. 
Although bacterial infection and chorioamnionitis have strong associations 
with preterm birth, bacterial infections do not always induce preterm labor.38, 39  
Furthermore, spontaneous preterm birth and PPROM have been observed in the 
absence of identifiable bacterial infection.  This supports the hypothesis that 
multiple factors may be responsible for these adverse birth outcomes and that 
etiological factors distinct from gestational infection play a role.   
Pregnant woman are exposed to a wide array of environmental pollutants, 
but few have been investigated epidemiologically for association with preterm 
birth and none have been satisfactorily investigated mechanistically.4  Although 
uninvestigated, it remains plausible that immunosuppression caused by toxicants 
may lead to increased incidence of infection and thereby increased risk of 
preterm birth.40  Pregnant women are also continuously exposed to 
environmental toxicants reported to stimulate pro-inflammatory cytokines in a 
wide range of non-gestational tissues.41-45  Polybrominated diphenyl ethers 
(PBDEs) are emerging toxicants of concern that have received limited attention 
regarding potential risks to human health and birth outcomes.46-53 
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PBDEs - exposure and impact. 
PBDEs are commercially-produced flame retardants consisting of two 
benzene (phenyl) rings linked by an ether bond with variable hydrogen to 
bromine substitutions (Figure 1.2).  Mixtures of PBDEs have been used in a wide 
array of consumer products including textiles, plastics, building materials, 
electronics and insulation to reduce the risk of spontaneous combustion and 
retard fire escalation.  These compounds are not chemically bound to the 
products and thus may leech into the environment.  Because of their chemical 
structure, several of the 209 PBDE congeners tend to be environmentally 
persistent and bioaccumulative.54   
Because of their environmental persistence and toxicity, the US EPA has 
identified PBDEs as a priority human health concern.55  Production of penta-BDE 
(tri- to hexa-BDE mixtures) and octa-BDE (hexa- to nona-BDE mixtures) ceased 
in the United States in 2004 by voluntary agreement of the manufacturer, and the 
European Union passed legislature to prohibit all penta- and octa-BDE use as of 
August 2004 (short-term deca-BDE extension granted Oct 2005).56  Recently, the 
4th meeting of the Convention of Parties of the Stockholm Convention on 
Persistent Organic Chemicals listed tetra-, penta-, hexa- and hepta-BDEs as 
persistent organic compounds, effectively banning their use in over 160 
countries.57  On the national level only Sweden has prohibited the use of deca-
BDE, although at the state level Maine has limited its use in residential 
furniture.58 
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Although US and European production of PBDEs has been limited in 
recent years, PBDE exposure remains a pertinent risk to human health.   The 
globalization of commerce has allowed the import and export of goods from 
regions with little or no regulation on PBDEs.  Furthermore, a wide stock of 
products containing lower brominated congeners still exists, allowing continued 
exposures.  Finally, many congeners have long environmental and biological 
half-lives.  This allows continued exposure long after the products containing 
these chemicals have been discarded.  Bioaccumulation through the food chain 
has been shown in many animal studies.59-61  Occupational exposure at recycling 
facilities has also been shown to result in high levels of PBDEs within human 
samples.62   
Since the 1970s, many researchers have reported PBDE concentrations 
and accumulation in human tissues (reviewed by Frederiksen 2009).58  In human 
biomonitoring studies, the PBDE congeners BDE-47, 99, 100 and 153 are most 
often detected and comprise the majority of total PBDE loading,48, 51, 53, 63, 64 but it 
is important to note that these are also the congeners most often assayed, 
potentially leaving other congeners underrepresented.  The human biomonitoring 
data primarily focus on breast milk and sera with few studies focusing on 
accumulation or partitioning among gestational compartments.  In a recent study 
conducted in the U.S., high levels of PBDEs were identified in fetal cord serum.48  
This is not unexpected, as PBDEs65 and chemicals with structural similarity to  
PBDEs have been shown to cross the placenta,66, 67 and North American serum 
levels are typically higher than other regions.58   
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To date, only two epidemiologic studies have been published detailing the 
effects of prenatal exposure to PBDEs.  Main et al. report a significantly higher 
risk of cryptorchidism for sons born to mothers with elevated PBDE levels in 
breast milk.68  In addition, Chao et al. found elevated levels of PBDEs in breast 
milk correlated with decreased infant birth weight, infant birth length, infant chest 
circumference and infant body mass index.69   
Animal studies show that PBDEs exhibit neurodevelopmental,70-73 
hepatic,74-79 immunological,80, 81 reproductive82, 83 and thyroid toxicity.78, 81, 84  
Rabbits orally exposed to PBDEs show decreased gestation length.82  Although 
studies of PBDE developmental effects have predominantly used 
pharmacological doses, recent studies have demonstrated that doses relevant 
for humans at critical developmental windows can have endocrine and neural 
effects.85, 86  Further research is needed to identify how these animal findings 
translate to humans and to understand the dose-response relationships for both 
individual PBDEs and PBDE mixtures. 
Unpublished studies from our laboratory have shown that PBDEs act as 
pro-inflammatory stimulants of cytokine release from human gestational 
membrane cell isolates.  Isolated human amnion epithelial cells were shown to 
secrete IL-6 into the surrounding medium in response to treatment with 500 nM 
concentrations of BDE-47, BDE-99, BDE-100 or BDE-153.  Primary cultures of 
human amnion fibroblast cells showed similar, but less sensitive effects.  
Treatments of 10 uM BDE-153, 60uM BDE-47, or 60 uM BDE-100 all showed 
significantly elevated IL-6 secretion into the surrounding media compared to the 
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levels seen in solvent treated controls.  Although compelling, these results were 
obtained with a low n and are yet to be confirmed.  
Because of their environmental persistence, ubiquitous exposure, 
bioaccumulation and toxcicity, PBDEs warrant further investigations to identify 
their potential involvement in adverse birth outcomes. 
 
Research objectives.  
The research contained in this dissertation is designed to test the 
hypothesis that polybrominated diphenyl ethers bioaccumulate in the human 
gestational compartment and stimulate cytokine secretion from human 
gestational membranes.  The specific aims of this research are to 1) Identify 
congener-specific PBDE abundances in the human gestational membranes, and 
amniotic fluid; and 2) Evaluate lipopolysaccharide- and PBDE-induced cytokine 
secretion from human gestational membranes using punch and transwell-
mounted in vitro explant culture systems.  Together these background data 
provide support for this investigation into the induction of inflammatory cytokines 
within the gestational membranes using PBDEs in an in vitro explant culture 
system.  In the long term, the results from these investigations will hopefully 
provide the basis for future research into the toxicological mechanisms of 
preterm birth and PPROM, resulting in enhanced prediction and prevention of 






















   
Figure 1.1.  Anatomy of the pregnant uterus.  Inset: histological section of 
gestational membrane. Diagram of pregnant uterus adapted from A.D.A.M. Interactive 
Anatomy 2009.  Histological image by Mark Miller. 


























Figure 1.2. Generic structure of polybrominated diphenyl ethers.  Hydrogen to 
bromine substitutions at each of the 10 open positions around the phenyl rings 
allow 209 distinct congeners.   
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Polybrominated diphenyl ethers (PBDEs) in human gestational membranes 





   Polybrominated diphenyl ethers (PBDEs) have been incorporated into 
many consumer products as flame retardants.  Due to their persistence and 
ability to bioaccumulate, PBDEs are ubiquitous in human blood and breast milk 
samples from industrialized nations.  Although there exists a potential for 
environmental pollutants such as PBDEs to adversely impact birth outcomes and 
perinatal health, reports of PBDE levels in human reproductive tissues are 
limited.  The aim of the current study is to evaluate the total levels and congener-
specific profiles of PBDEs from human extraplacental gestational membranes.  
Gestational membranes from five term pregnancies were obtained from non-
laboring caesarian deliveries at the University of Michigan Women’s Hospital 
Birth Center.  Duplicate samples were extracted and analyzed by GC-MS for 
twenty-one PBDE congeners.  Total PBDE loading was 17.4 ± 3.9 pg/g tissue 
(5.62 ± 1.28 ng/g lipid). Seventy-eight percent of the total measurable PBDE 
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loading was due to BDEs 47, 49, 99, 100, and 153, with measured values of 
3.63, 3.15, 3.05, 1.74, and 1.90 pg/g tissue (1170, 1018, 983, 561, and 612 pg/g 
lipid), respectively.  The remaining 28% was comprised of BDEs 17, 28, 66, 71, 
85, and 154.  No octa-, nona- or deca- BDEs were identified.  Although 
previously unreported in the human gestational compartment, BDE 49 comprised 
17% of the total PBDE level.  This work establishes baseline accumulated levels 




   Polybrominated diphenyl ethers (PBDEs) are commercially produced 
synthetic flame retardants consisting of two phenyl rings linked by an ether bond 
with variable hydrogen to bromine substitutions. Mixtures of PBDEs have been 
used in textiles, plastics, building materials and insulation.  Because of their 
chemical structure, several of the 209 PBDE congeners tend to be 
environmentally persistent and bioaccumulative.1  In human measurement 
studies, congeners BDE-47, 99, 100 and 153 are most often detected and 
comprise the majority of total PBDE loading.2-4  Since 1970, over 50 reports have 
identified PBDEs in human adipose, liver, breast, whole blood, serum, breast 
milk, fetal cord blood and placenta (reviewed by Hites).1  Furthermore, several 
studies have begun to address gestational compartment dynamics through 
paired sampling of maternal blood, fetal blood and placenta,3, 5-8 although none to 
date has addressed the extra-placental maternal/fetal gestational membranes.  
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In animal studies, PBDEs exhibit neurodevelopmental, 9, 10 hepatic,11, 12 
immunological13, 14 and thyroid toxicities.12  Rabbits orally exposed to PBDEs 
show decreased gestation length.15  Because of their environmental persistence 
and toxicity, the US EPA has identified PBDEs as a priority human health 
concern.16  Production of penta-and octa-substituted congeners ceased in 2005 
in the USA, and the European Union passed legislation to prohibit all PBDE use 
after July 2006 (a short-term extension for deca-BDE was granted in October 
2005).  Although U.S. and European production of PBDEs has ceased except for 
BDE 209, many PBDEs remain a pertinent risk to human health due to 
production in other regions, import/export of goods containing PBDEs, the wide 
stock of PBDE-containing materials in-use, and environmental persistence.17 
Extraplacental gestational membranes are composed of the amniotic, 
chorionic and decidual layers that surround the fetus and create a protective 
barrier during gestation.  Minimally vascularized and containing dense collagen, 
the extraplacental membranes are distinctly different from the highly vascularized 
placental disk used to transfer oxygen, nutrients and waste products between 
maternal and fetal blood.  Additionally, the extraplacental membranes play an 
important role in parturition, producing both cytokines and prostaglandins in all 
three layers during labor.18, 19  Cytokines and prostaglandins have been closely 
linked to the biological processes of birth including dynamic cervical 
remodeling,20 uterine contractility21 and gestational membrane rupture.22   
Rupture of these membranes plays a key role in term and preterm parturition.  
Recent increases in the rate of preterm premature rupture of membranes 
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(PPROM) has made it a leading cause of preterm birth, particularly in African-
American women, and often results in fetal morbidity or mortality.23  The causes 
of PPROM are still to be determined, and the role of environmental pollutants 
such as PBDEs has yet to be addressed. 
Americans are ubiquitously exposed to PBDEs, primarily through dust and 
diet.24  The 2003-2004 National Health and Nutrition Examination Survey 
(NHANES) identified measurable PBDE levels in 89% (2040 of 2305) of 
randomly selected blood serum samples.  Once in the maternal blood circulation, 
PBDEs may access the gestational membranes directly or indirectly.  The spiral 
arteries of the uterus supply blood to the decidua, providing a direct route of 
transfer to the membranes.  In addition, previous studies have shown that 
PBDEs can enter the gestational compartment and fetal blood circulation, 
presumably by crossing the placental blood interface.25, 26  It is also possible that 
PBDEs reach the gestational membranes indirectly from the fetal compartment 
through the amniotic fluid.  Although no studies to date have assessed PBDE 
levels in the amniotic fluid, studies of structurally similar compounds 
(polychlorinated biphenyls) have shown high levels in human amniotic fluid.27  
Because of the likely PBDE exposure of gestational membranes and their critical 
role in parturition, an assessment of PBDE deposition in the human gestational 
membranes was undertaken.       
 The aim of this study was to determine the total PBDE concentrations and 
congener-specific deposition profiles in human extra-placental gestational 
membranes from women in southeast Michigan.  Twenty-one PBDE congeners 
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(BDEs 17, 28, 47, 49, 66, 71, 75, 85, 99, 100, 138, 153, 154, 166, 183, 190, 203, 
206, 207, 208 and 209 [deca-]) were measured in the present study.      
 
Materials and Methods 
 
Sample collection. 
 From November 2007 through January 2008 duplicate extraplacental 
membranes samples were obtained from five healthy non-laboring women 
undergoing scheduled caesarean section deliveries at 37-39 completed weeks 
gestation at the University of Michigan Women’s Hospital Birth Center in Ann 
Arbor, Michigan.  Exclusion criteria included cigarette smoking, prescription of 
antibiotics in the past two weeks, collagen vascular disease, 
immunocompromised conditions, bacterial vaginosis or clinical chorioamnionitis 
(as noted in the chart or suspected by attending physician), cervical cerclage, 
third trimester bleeding, major maternal medical conditions (e.g., chronic renal 
disease, sarcoidosis, hepatitis, HIV), pre-eclampsia, diabetes, multifetal 
pregnancy, or any other condition which would require the tissue to be sent to 
pathology.  Personal identifiable information was not collected, in compliance 
with the University of Michigan Institutional Review Board requirements.  The 
investigators had no direct interaction with the human subjects and the tissues 
collected would have been otherwise discarded.   
Following delivery, placentae with attached membranes were transported 
to the laboratory.  Full thickness membranes were separated from the placental 
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disk, allowing a 3 cm margin to prevent sampling from the transitional zone.  
Each 1 g sample was compiled from 5-7 random collections of full-thickness 
membranes and was placed into a glass sample vials with Teflon® lined caps.  
To prevent contamination of samples, all stainless steel instruments and 
glassware used for collection were baked at 500 ⁰C and rinsed with 
homogenization solvent immediately prior to use.  Laboratory practices followed 
universal safety precautions for handling human tissue (e.g., personnel 
vaccination for hepatitis B and wearing of laboratory safety glasses, gloves, face 
mask and lab coat when handling tissues). 
 
Analysis of lipid content.  
 Replicate 1 g tissue samples were homogenized using a Polytron® 
PT2100 tissue homogenizer (Kinematica, Bohemia, NY) in 25 ml hexane/ethyl 
acetate (9:1 v/v), or for comparison, in 25 ml hexane/carbon tetrachloride (4:1 
v/v).  HPLC grade hexane, carbon tetrachloride and ethyl acetate were 
purchased from Fisher Scientific (Fair Lawn, NJ), Acros Organics (Geel, 
Belgium) and Sigma (St. Louis, MO), respectively.  Samples were centrifuged 
and the organic fraction was transferred to pre-weighed glass beakers.  The 
solvent was volatilized under a N2 (Cryogenic Gasses, Detroit, MI) stream, and 
the remaining lipid was maintained overnight at 100 °C to remove any remaining 
water.  The glass beakers were then reweighed to determine the lipid content of 




 Replicate 1 g samples from each caesarean delivery were homogenized 
using a Polytron® PT2100 tissue homogenizer in 25 ml hexane/ethyl acetate (9:1 
v/v).  The organic fractions were transferred to volumetric test tubes and 
evaporated to 1 ml under a N2 stream.  Samples were spiked with internal 
standards (CB IUPAC Nos 136 and 204).  Each sample (2 μl injection) was 
analyzed for 21 PBDE congeners by GC-MS (Agilent 6890/5973, Palo Alto, CA, 
USA) using negative chemical ionization mode and a DB-5 column (30 m, 0.25 
mm id, 0.25 μm film thickness; J&W Scientific, Folsom, CA, USA).  The carrier 
gas was helium (flow rate of 0.7 mL/min, inlet pressure of 5.43 psi, average 
velocity of 31 cm/s), and methane was the reagent gas.  In all runs, the injector 
was set at 280 °C.  The oven temperature started at 80 °C, held for 2 min, then 
ramped at 10 °C/min to 300 °C, and held for 46 min.  A separate run was made 
for BDE-209 using a temperature program that avoided fragmentation.  In the 
latter case, the initial temperature again was 80 °C, held for 2 min, then ramped 
at 50 °C/min to 300 °C and held for 40 min.  Calibration standards included BDEs 
17, 28, 47, 49, 66, 71, 75, 85, 99, 100, 138, 153, 154, 166, 183, 190, 203, 206, 
207, 208 and 209.  Method detection limits (MDLs) were estimated based on 
three times the standard deviation of seven low concentration standards and 
then dividing by the collected mass (g) of the samples.  The estimated MDLs 
were 0.010-0.020 ng/g for tri- through hexa-BDEs, 0.020-0.040 ng/g for hepta- 




 Data for BDEs 17, 28, 47, 49, 66, 71, 85, 99, 100, 153, and 154 are 
represented as the mean ± SEM.   Two replicate sample measures of BDE 
congeners were averaged and a grand mean was calculated for each BDE 
congener (N=5).   Measurements below the MDL were assigned a value of one-
half the MDL.  Congener concentration as a percent of total PBDE loading was 
calculated by averaging the percent each congener constituted from each 
independent sample.  BDEs 75, 138, 166, 183, 190, 203, 206, 207, 208 and 209 
(deca) were not detected in any samples and have been excluded from 
subsequent data analysis.  
 
Results and Discussion 
 
 The lipid content of 1-g gestational membrane samples using the 
hexane/carbon tetrachloride solvent averaged 0.30%.  Comparable results 
(0.31%) were obtained using hexane/ethyl acetate. Based on these results, 
hexane/ethyl acetate was used for tissue extractions prior to PBDE analysis. The 
lipid content of the human gestational membranes appears lower than the lipid 
content reported for the human placenta.6, 28 
  On a tissue weight basis, the mean total PBDE concentration in the 
gestational membranes was 17.41 ±3.98 pg/g (n=5; Table 2.1.).  Values for each 
sample are the average of two replicate measures.  From this a grand mean was 
calculated based on the sample means (N=5).  On a lipid weight basis, the total 
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PBDE level was 5.62 ± 1.28 ng/g (range from 3.06 to 9.53 ng/g) in the 
gestational membranes (Table 2.1.).  Lipid contents for all human gestational 
membranes measured were 0.31%.  
 The individual congener profile is shown in Figure 2.1.  Congeners 
exceeding 0.5 ng/g lipid were BDEs 47 (1.17 ng/g), 49 (1.02 ng/g), 99 (0.98 
ng/g), 100 (0.56 ng/g) and 153 (0.61 ng/g).  Congeners detected at lower 
concentrations were BDEs 17 (0.15 ng/g), 28 (0.14 ng/g), 66 (0.06 ng/g), 71 
(0.32 ng/g), 85 (0.25 ng/g) and 154 (0.36 ng/g).  BDEs 75, 138, 166, 183, 190, 
203, 206, 207, 208 and 209 (deca) were not identified in any samples.    
 Individual congener contributions to total PBDEs were assessed for each 
sample.  Percent of total (mean±SEM; N=5) is shown in Figure 2.2.  Of the total 
5.62 ng/g lipid PBDE loading, BDEs 47, 99, 49, 100, and 153 comprised 22, 21, 
17, 12 and 11 %, respectively, for a total of 83%.  Additional congeners identified 
and contributing to the total tissue concentration include BDEs 17 (2%), 28 (2%), 
66 (<1%), 71 (6%), 85 (3%) and 154 (4%).  BDEs 75, 138, 166, 183, 190, 203, 
206, 207, 208 and deca-BDE were below the limit of detection in all samples 
tested and were therefore excluded from this analysis.  When comparing the 
major contributing congeners analyzed in various studies, this composition is 
similar to the profiles observed in fish,29 birds,30 air,31 and sediment32-34 in the 
Great Lakes region. 
 This is the first report of PBDE levels in human extraplacental gestational 
membranes.  These PBDE levels are several orders of magnitude lower than 
those reported by Doucet et al. in placenta proper from North America.35  Doucet 
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et al. report highly variable levels ranging from >20,000 ng/g lipid in 2004 to ~200 
ng/g lipid in 2005.  Increased vascularization may lead to increased burdens in 
the placenta, although the relative PBDEs in the placental tissue versus blood 
remaining in the placental sample has yet to be addressed.   The impact of lipid 
weight adjustment from tissue weight could not be addressed because placental 
lipid content was not reported.  A similar study of European women showed 
significant variation in placental lipid content between Denmark and Finland.8  
When compared with placenta proper from European women (reviewed by 
Frederiksen et al.) the PBDE levels reported in this study are 3-5 fold higher 
those previously measured (1.18-1.9 ng/g lipid).24  This is not unexpected as 
previous studies suggest biotic and abiotic PBDE concentrations in North 
America may be several orders of magnitude higher than those found in Europe1, 
24 and levels in gestational membranes appear to be several orders of magnitude 
lower than placenta.  It should also be noted that BDE congeners selected for 
measurement vary between studies and may contribute to the variation seen in 
total PBDE levels between studies.  
   Previous research has suggested BDEs with greater numbers of bromine 
atoms have shorter biological half lives.36  Thuresson et al. have estimated the 
biological half-lives of these large BDEs to range from 15 days (deca-BDE) to 97 
days (BDE 183) in human serum.  Relatively short biological half-lives in 
combination with minimal vascularization and potential steric hindrances of 
infiltration into the dense gestational membranes may contribute to our failure to 
identify higher order congeners in this study.  
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  The tetra-brominated congener BDE-49 has been identified as a major 
contributor to PBDE accumulation in fish,37, 38 including one report from the Great 
Lakes that found it to be the most abundant congener.39  Interestingly, our data 
also show high levels of BDE-49, which has not been previously reported in the 
gestational compartment.  BDE-49 comprised 17% of the total PBDE 
concentration.  Because BDE-49 is often unreported (and presumably 
unmeasured) in the vast majority of human research, our results suggest that 
PBDE levels may be being underestimated by as much as 14-19%. 
Oral exposure to PBDEs decreases gestational length in rabbits,15 but a 
mechanism explaining this finding is lacking.  Because the extra-placental 
gestational membranes play critical roles in pregnancy and parturition,18-22 they 
may be important targets of PBDE activity.  Current research suggests a possible 
mechanism by which PBDE stimulation of the gestational membranes may 
activate parturition pathways via reactive oxygen species generation.  Penta-
BDE increases reactive oxygen species in neutrophil granulocytes in vitro.40  
Reactive oxygen species are potent activators of the nuclear factor-kappa B (NF-
κB) nuclear transcription pathway, which activates cytokine and prostaglandin 
production (reviewed by Schoonbroodt and Piette).41  Because cytokines and 
prostaglandins are important stimulants of parturition,42-44 premature activation of 
this pathway by PBDEs could contribute to preterm birth.  Further research is 
needed to investigate this hypothesis, and to assess whether a link can be made 
between PBDE exposure and preterm birth in women.  The identification of total 
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and congener-specific PBDE levels within the human gestational membranes in 
the present report is an important first step for further research.   
 This research provides evidence of accumulation for individual PBDE 
congeners in human gestational membranes.  These initial data indicate a need 
for further investigation into the partitioning of specific PBDE congeners within 
the fetal membranes and the greater gestational compartment.    Furthermore, 
these data suggest that evaluation of PBDE effects on gestational membranes 
may be warranted.  The levels reported here for human tissue accumulation will 
allow assessment of the relevance of PBDE concentrations on gestational 
membrane responses in future experiments.    
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Table 2.1.  Total PBDE loading in human maternal- fetal membranes.  Total measured concentrations of PBDEs 
represented as pg/g tissue and ng/g lipid (mean±SEM).  All process blanks were below the limit of detection.  N=5.  
Sample: 
PBDE Congener MDL 1 2 3 4 5       Mean (SEM) 
17 0.01 0.91 0.86 0.55 <0.01a <0.01a 0.46 (0.21) 
28 0.01 1.07 0.89 0.17 <0.01a <0.01a 0.43 (0.17) 
49 0.01  5.07 4.16 2.71 1.34 2.50 3.15 (0.68) 
71 0.02 1.23 1.46 0.49 0.97 0.83 0.99 (0.16) 
47 0.02  5.49 5.50 2.28 2.30 2.58 3.63 (0.54) 
66 0.02 0.53 0.35 <0.02a <0.02a <0.02a 0.18 (0.12) 
100 0.02  2.88 1.86 1.43 1.05 1.48 1.74 (0.22) 
99 0.02  4.17 3.26 2.77 2.62 2.41 3.05 (0.32) 
85 0.02 1.68 2.11 <0.02a <0.02a <0.02a 0.76 (0.32) 
154 0.01 3.83 1.38 0.31 0.01 0.01 1.11 (0.53) 
153 0.01 2.68   2.32   1.58   1.16   1.75 1.90 (0.36) 
 ∑PBDE 29.56 24.14 12.29 9.47 11.58 17.41 (3.98) 
ng/g LWb 9.53 7.79 3.97 3.06 3.73 5.62 (1.28) 
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a values falling below the MDL were assigned a value one-half the MDL.  






























































Figure 2.1.  PBDE congener concentrations in human gestational membranes. 


































































Figure 2.2.  PBDE congener concentration as percent of total PBDE loading.  
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Concentrations and speciation of polybrominated diphenyl ethers (PBDEs) 





   Polybrominated diphenyl ethers (PBDEs) are persistent organic 
chemicals used as flame retardants in textiles, plastics, and consumer products.  
Many of the 209 PBDE congeners have been classified as persistent organic 
pollutants at the 4th meeting of the Convention of Parties of the Stockholm 
Convention on Persistent Organic Chemicals.  Although PBDE accumulation in 
humans has been noted since the 1970s, few studies have investigated PBDEs 
within the gestational compartment and none to date has identified levels in 
amniotic fluid.  This study reports congener-specific PBDE concentrations in 
second-trimester amniotic fluid from fifteen women in southeast Michigan, USA.  
BDEs 17, 28, 47, 49, 66, 71, 75, 85, 99, 100, 138, 153, 154, 166, 183, 190, 203, 
206, 207, 208 and 209 were measured by GC/MS.  The average total PBDE 
concentration was 3,795 pg/ml amniotic fluid (range 337 – 21,842 pg/ml).  High 
levels of both higher and lower brominated PBDEs were identified.  The most 
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abundant congeners were BDE-138 (15% of the total BDE), 207 (15%), 47 
(10%), 208 (9.5%), and deca (8.4%).  BDEs 47 and 99 were identified in each 
sample.  These results show that high PBDE concentrations in amniotic fluid are 
common, and they suggest that amniotic fluid may participate in the transfer of 
PBDEs to the fetus, a previously undocumented exposure route.  The relatively 
high levels of PBDEs found in the human gestational compartment warrant 
further investigations of exposure pathways and potential impacts to birth 




   Polybrominated diphenyl ethers (PBDEs) are a class of widely used 
brominated flame retardants that have been incorporated into many consumer 
electronics, textiles and furniture.  These compounds are not chemically bound 
within the products and thus may leech into the environment.  Although 
production of penta-BDE (tri- to hexa-BDE mixtures) and octa-BDE (hexa- to 
nona-BDE mixtures) ceased in the United States in 2004, PBDE exposure 
remains a concern due to production in other regions, import/export of goods 
containing PBDEs, the wide stock of PBDE-containing materials remaining in 
use, and PBDE environmental persistence.1  In addition, deca-BDE (nona- to 
deca-BDE mixtures) production continues at increasing rates.  
Because of their environmental persistence and toxicity, the US EPA has 
identified PBDEs as a priority human health concern.2  Recently, the 4th meeting 
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of the Convention of Parties of the Stockholm Convention on Persistent Organic 
Chemicals listed tetra-, penta-, hexa- and hepta-BDEs as persistent organic 
compounds, effectively banning their use in over 160 countries.3  Currently, the 
human reproductive and developmental health risks associated with PBDE 
exposure have not been thoroughly addressed and many uncertainties remain.  
Animal studies show that PBDEs exhibit neurodevelopmental,4, 5 hepatic,6, 7 
immunological8, 9 and thyroid toxicity.7  Rabbits orally exposed to PBDEs show 
decreased gestation length.10  Further research is needed to identify how these 
animal findings translate to humans and to understand the dose-response 
relationships for both individual PBDEs and PBDE mixtures. 
Human amniotic fluid plays an important role in gestation.  Amniotic fluid 
begins to collect within the amniotic cavity during the third week of gestation and 
increases in volume through the 35th week of gestation.  During the first 20 
weeks of gestation amniotic fluid is primarily formed through maternal secretion.  
The volume of fluid increases throughout the second trimester from 
approximately 200 ml at 16 weeks gestation to a peak of 1000 ml at 28 weeks 
gestation.11  Amniotic fluid surrounds the fetus until birth, providing nourishment 
from early stages of pregnancy until birth.  Throughout gestation, the fetus is 
continuously swallowing and “inhaling” amniotic fluid.  Intake into the 
gastrointestinal and respiratory tracks along with dermal exposure provide a 
direct route of transport into the fetus for toxicants that enter the amniotic 
compartment.  Historically, amniotic fluid analysis has been used to confirm fetal 
exposure to nicotine and cotinine, but is not a suitable method for routine 
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assessment of prenatal drug/toxicant exposure due to the invasive nature of 
sample collection potentially resulting in harm to the fetus.12   
Since the 1970s, many researchers have reported PBDE concentrations 
and accumulation in human tissues (reviewed by Frederiksen 2009).13  Although 
the human biomonitoring data primarily focus on breast milk and sera, several 
studies have begun to address the partitioning among and between gestational 
compartments through paired sampling of maternal blood, fetal blood and 
placenta.14-18  Recently, we identified PBDE accumulation in human gestational 
membranes.19  To date, however, the potential for PBDEs to accumulate in 
human amniotic fluid has not been addressed. 
The aim of this study was to measure PBDE profiles, including congener-
specific and total PBDE concentrations, in amniotic fluid collected from women in 
southeast Michigan, USA.  This information will help to evaluate the significance 
of PBDE transport into amniotic fluid and from the amniotic fluid into other 
gestational matrices, including the developing fetus.  
 
Materials and Methods 
 
Sample collection. 
 In February and March 2009, excess clinical amniotic fluid samples, 
typically 15 ml, were collected at the University of Michigan Women’s Hospital in 
Ann Arbor, Michigan, USA.  Deidentified samples containing excess amniotic 
fluid from 15 women undergoing clinically-indicated amniocentesis for 
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identification of fetal genetic aberrations during their second trimester were 
analyzed for PBDE profiles.  An average volume of 15 ml of amniotic fluid per 
sample was received in the cytogenetics laboratory and centrifuged at 280 g for 
10 min to remove the cellular component.  The excess supernatant was 
transferred into tubes without patient identification and stored at -80 °C.  The 
resulting supernatant was used for all analyses. 
The 15 women represent an anonymous sample where personal 
identifiable data were not collected, in compliance with the University of Michigan 
Institutional Review Board requirements.  The investigators had no direct 
interaction with the human subjects.  All amniotic fluid specimens used in this 
study would have been otherwise discarded.   
 
Analysis of lipid content.  
 Amniotic fluid supernatants were evaluated independently for lipid content.  
For each amniotic fluid sample, 1 ml of amniotic fluid was denatured with 1 ml 
HCl followed by 6 ml isopropyl alcohol.  Samples were then extracted using 5 ml 
methyl tert-butyl ether and hexane (1:1).  Sample fractions were separated by 
centrifugation and the organic fraction collected.  The extraction process was 
repeated three times and organic fractions were combined in a previously 
weighed beaker.  The organic fraction was volatilized under a flowing nitrogen 
stream until dry, and then baked at 100°C for 12 h to remove all water.  Beakers 




 Amniotic fluid supernatants were evaluated for 21 PBDE congeners.  For 
each amniotic fluid sample, 7 ml of amniotic fluid was denatured with 2 ml HCl, 
followed by 12 ml isopropyl alcohol.  Samples were then extracted using 10 ml 
methyl tert-butyl ether and hexane (1:1).  Sample fractions were separated by 
centrifugation and the organic fraction collected.  The extraction process was 
repeated three times and organic fractions were combined and volatilized under 
a flowing nitrogen stream until nearly dry.  Samples were resuspended in 5 ml 
hexane and cleaned with 3 ml sulfuric acid.  The organic fraction was removed 
and neutralized using sodium carbonate. 
Instrumental analyses used GC/MS (Agilent 6890, Palo Alto, CA, USA), 
negative chemical ionization mode, a DB-5 column (30m, 0.25 mm i.d., 0.25 μm 
film thickness, J&W Sci, Folsom, CA, USA) and a 2 μl splitless injection.  The 
carrier gas was helium (0.7 ml/min, inlet pressure 5.43 psi, average velocity 37 
cm/s), and methane was the reagent gas.  The injector was set at 280 oC.  The 
oven temperature started at 80 oC, held for 2 min, ramped at 10 oC/min to 300 
oC, and held for 40 min. Calibration standards included BDEs 17, 28, 75, 49, 71, 
47, 66, 100, 99, 85, 154, 153, 138, 166, 183, 190, 203, 208, 207, 206 and 209 
(Cambridge Isotope Laboratories, Inc., Andover, MA, USA). Standards were run 
for a wide range of concentrations (100 to 5000 ng/ml) that encompassed the 
range expected in field samples.  The MS was operated in selected ion 
monitoring mode, and quality matching routines included at least two ions.  
Structural verification used additional ions and confirmed spectra by requiring 
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proper ratios of ions for each analyte.  Complete details of the instrumental 
analysis have been published previously.20  
 
Quality assurance. 
In parallel with the analyses, field, lab and method blanks were processed 
and shown to be clear of detectable contamination.  Linearity and drift checks 
were analyzed with each sample batch.  Repeat analysis of a standard injected 
every fifth sample varied by less than 10% and linearity plots produced r2 values 
greater than 0.999.  Surrogate spike recoveries ranged from 82-106%. 
 
Data analysis. 
 Measurements falling below the method detection limit (MDL) were 
assigned a value of one-half the MDL.  Descriptive statistics, including the mean, 
the standard error of the mean, median, range, and the percentage of 
observations above the MDL, were calculated for each congener.  For each 
sample, the total PBDE (∑PBDE) concentration was calculated as the sum of the 
21 congeners, and a grand mean was calculated as the average of the sample 
∑PBDEs.  Concentrations are expressed as volumetric and lipid-based fractions.  
Congener-specific abundances were calculated for each sample as the congener 
concentration divided by the total PBDE loading and expressed in percent.  
Sample statistics utilized the mean, median and sum of these abundances.  The 
relationship of lipid content to BDE levels was evaluated using the Spearman 
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rank order correlation.  Relationships among BDE levels were also evaluated 
using the Spearman rank order correlation. 
 
Results and Discussion 
 
Lipid content. 
 The lipid content averaged 0.94 ± 0.03% and ranged from 0.74 to 1.25%.  
The lipid content reported here is lower than a previous report that found values 
as high as 22.5 ± 1.2% in human amniotic fluid.21  The difference between the 
studies is likely due to the use of amniotic fluid supernatant in the present study.  




  Concentrations varied widely among the samples, but BDE-47 and 99 
were found in all samples tested.  On a volumetric basis, the ∑PBDE 
concentration in amniotic fluid averaged 3,795 ± 1,529 pg/ml (median = 1,253 
pg/ml; n=15; Table 3.1), and individual samples ranged from 337 to 21,842 
pg/ml.  On a lipid basis, this is equivalent to a ∑PBDE concentration of 404 ± 163 
ng/g lipid (median = 133 ng/g).   
The correlation between lipid content and ∑PBDE concentration was low 
and not statistically significant (p=0.86).  Similarly, no correlation was found 
between lipid content and any of the individual congeners (p=0.15-0.99).  These 
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results are not unexpected given the small amount of variation in lipid content.  
For example, the highest ∑PBDE concentration (21,842 pg/ml = 2,324 ng/g lipid) 
was found in a specimen with a lipid content of 1.01%, just slightly above the 
study average.   
Significantly, the highest ∑PBDE level in amniotic fluid is comparable to 
the highest U. S. reports of PBDE levels in breast milk (1,900 ng/g lipid),22 
although it is below that reported in adipose tissue (9,600 ng/g lipid).23  
Interestingly, tri- to octa-congeners accounted for 82% of the ∑PBDEs in the 
sample with the highest ∑PBDE level well above the 60% average for all 
samples.   
Many factors can affect an individual’s PBDE body burden and the 
concentrations of PBDEs found in amniotic fluid.  These include variation in an 
individual’s PBDE exposure before and during pregnancy, the number of 
previous children for each woman, the timing of amniocentesis within the second 
trimester, and the woman’s age.  Due to the nature of sample collection, these 
factors were not controlled in this study. 
 
Congener abundances. 
 The speciation of PBDEs found in human amniotic fluid is shown in Figure 
3.1.  The median congener abundances, interquartile range and max/min values 
are displayed in Figure 3.2.  We identified a wide range of congeners in this 
study, and all 21 target congeners were measured above MDLs in at least three 
of the fifteen samples (20%).  As noted earlier, BDE-47 and 99 were identified in 
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all samples; additionally, BDE-100, 209, and 17 were identified in 93%, 80% and 
80% of samples, respectively.  Based on median abundances, the dominant 
congeners were BDE-206, 209, 203, 208 and 207, representing 23, 16, 12, 10 
and 9%, respectively, of the ∑PBDEs.   
The contribution of PBDE homologues are shown in Figure 3.3.  The 
PBDE profile of the amniotic fluid shows an abundance of PBDE congeners with 
high numbers of bromine substitutions, representing a shift toward higher 
brominated congeners as compared to profiles reported for breast milk and 
serum.13  This shift may be due to altered partitioning in amniotic fluid or 
differences in exposure for our sampling population.  Although the lower 
brominated congeners (tri- through octa-BDEs) are no longer produced in the 
United States, the homologue profile shows that they still constitute the bulk 
(60%) of the ∑PBDE loading.  Mobilization of body burdens, exposure from the 
import/export of goods containing PBDEs, the wide stock of PBDE-containing 
materials still in use, and environmental persistence may explain the legacy of 
these congeners we see accumulating in nascent amniotic fluid. 
 
PBDE correlations. 
 The Spearman rank order correlations comparing the PBDE 
measurements from human amniotic fluid are detailed in Table 3.2.  A strong 
correlation was seen between the deca- and nona-BDE congeners.  This is not 
surprising since nona-BDEs are often found as contaminants of the deca-BDE 
commercial mixture, and therefore we would expect individuals exposed to deca-
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BDE to also be exposed to nona-BDEs.  Stapleton et. al have shown that deca-
BDEs can break down into nona-congeners in fish.24  Interestingly, BDE-71 also 
showed a strong correlation with the deca- and nona- congeners.   Although not 
previously reported in any system, this correlation raises the question of whether 
the higher order congeners can break down into lower order congeners.   
 Strong correlations were seen among the specific homologues.  Hexa-
BDEs 138, 153 and 154 were all found to have significant correlations with each 
other.  In addition, tetra-BDE congeners 49, 71 and 75 also showed significant 
correlations.  This is expected because these BDE homologues are often found 
together in the commercial mixtures of PBDE used prior to 2004.   
The present study is the first to report concentrations and congener 
abundances for PBDEs within human amniotic fluid.  Because amniotic fluid 
surrounds the fetus during gestation, toxicant concentrations in amniotic fluid are 
likely correlated to exposure to the fetus.  Although our sample size is modest, 
the measured concentrations appear significant, and suggest the need for further 
investigation into the partitioning of PBDEs among the amniotic fluid, the 
developing fetus, and the maternal circulation.  Our results suggest the need for 
further investigation of an exposure pathway not considered previously: the 
amniotic fluid-to-fetus route. 
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Table 3.1.  PBDE Concentration in Human Amniotic Fluid. (N=15) 
  
  Amniotic Fluid Concentration (pg/ml fluid)    
PBDE MDL Mean (SEM) Median Range N>MDL (%)      
17 0.01 108 (91) 11 <MDL-1237 80 
28 0.02 206 (206) <MDL < MDL -1374 27 
47 0.05 380 (295) 49   9.11-4491 100 
49 0.02 50 (43) <MDL < MDL -655 40 
66 0.02 11 (6) 4.92 < MDL -90 53 
71 0.01 31 (29) <MDL < MDL -434 33 
75 0.02 12 (8) <MDL < MDL -119 40 
85 0.01 75 (25) 24 < MDL -308 73 
99 0.06 188 (95) 31   4-1124 100 
100 0.05 187 (127) 37 < MDL -1916 93 
138 0.01 565 (312) 37 < MDL -4456 67 
153 0.03 143 (77) 18 < MDL -1119 67 
154 0.02 192 (140) 36 < MDL -2134 53 
166 0.01 20 (18) <MDL < MDL -273 20 
183 0.05 28 (17) <MDL < MDL -263 40 
190 0.05 36 (25) <MDL < MDL -371 27 
203 0.05 177 (61) 97 < MDL -839 60 
206 0.22 149 (69) 79 < MDL -957 60 
207 0.22 559 (346) 71 < MDL -5213 67 
208 0.22 362 (181) 189 < MDL -2598 67 
209 0.65 319 (102) 133 < MDL -1286   80 
      
∑PBDE (pg/ml fluid) 3795 (1529) 1253 337-21842 
∑ Tri-octaBDEs 2407 (1183) 788 81-17977  
      
∑PBDE (ng/g lipid) 404 (163) 133 36-2324  
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Figure 3.2.  Congener profile for PBDEs in human amniotic fluid.  Box plots present median and interquartile range.  





















































































Figure 3.3.  Profile of PBDE homologues in human amniotic fluid. The percent contribution based on median abundances 
for each homologue group (tri-, tetra-, penta-, etc.) is listed above the diagram.  The PBDE median values (pg/ml) used to 

























































17 0.09  0.04  0.04  0.12  0.01  0.35 0.00 0.00 0.47 0.01 0.01 0.31 0.45 0.58  0.05 0.80 0.08 0.06 0.11 0.21 0.00  0.00 
BDE-
28    0.02  0.06  0.03  0.38  0.73 0.17 0.29 0.50 0.19 0.91 0.81 0.03 0.04  0.21 0.57 0.18 0.18 0.22 0.16 0.37  0.70 
BDE-
75       0.00  0.00  0.31  0.36 0.04 0.16 0.61 0.37 0.32 0.40 0.13 0.22  0.43 0.29 0.11 0.06 0.07 0.09 0.04  0.30 
BDE-
49          0.00  0.36  0.29 0.04 0.19 0.63 0.41 0.26 0.37 0.23 0.26  0.29 0.37 0.15 0.11 0.10 0.18 0.04  0.28 
BDE-
71             0.51  0.58 0.10 0.22 1.00 0.71 0.76 0.94 0.17 0.58  0.83 0.66 0.02 0.02 0.01 0.02 0.12  0.84 
BDE-
47                0.04 0.00 0.02 0.08 0.00 0.00 0.03 0.30 0.29  0.21 0.43 0.77 0.51 0.40 0.39 0.00  0.00 
BDE-
66                   0.20 0.31 0.00 0.02 0.05 0.00 0.10 0.03  0.02 0.25 0.29 0.17 0.42 0.87 0.09  0.04 
BDE-
100                      0.00 0.14 0.00 0.00 0.11 0.27 0.51  0.07 0.37 0.23 0.10 0.11 0.15 0.00  0.00 
BDE-
99                         0.17 0.00 0.02 0.17 0.09 0.57  0.31 0.36 0.13 0.07 0.13 0.08 0.00  0.00 
BDE-






154                               0.00 0.04 0.09 0.06  0.11 0.21 0.71 0.65 0.62 0.33 0.00  0.00 
BDE-
153                                  0.02 0.33 0.31  0.08 0.90 1.00 0.55 0.49 0.55 0.00  0.00 
DBE-
138                                     0.16 0.10  0.13 0.99 0.04 0.17 0.15 0.38 0.07  0.00 
BDE-
166                                        0.00  0.45 0.70 0.79 0.73 0.65 0.05 0.18  0.13 
BDE-
183                                           0.17 0.79 0.41 0.48 0.64 0.43 0.58  0.21 
BDE-
190                                              0.82 0.58 0.47 0.73 0.42 0.16  0.05 
BDE-
203                                                 0.95 0.59 0.96 0.80 0.78  0.77 
BDE-
208                                                    0.00 0.00 0.00 0.15  0.95 
BDE-
207                                                       0.00 0.00 0.07  0.70 
BDE-
206                                                          0.00 0.07  0.86 
BDE-
209                                                             0.08  0.72 
∑PBDE                                                                0.00 
 
a P-values are displayed for each pair of congeners.  Statistically significant P-values less than 0.05 are in bold.                   
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Comparison of LPS-stimulated release of cytokines in punch versus 





 Cytokine signaling within the amnion, chorion and decidua plays an 
important role in membrane rupture and therefore the timing of birth.  The 
predominant in vitro explant culture system for evaluating cytokine induction in 
human gestational membranes has been the free-floating biopsy punch culture.  
Punch systems have been used to investigate the impact of various toxicants, 
pharmaceuticals and genetic variation on expression of pro-inflammatory 
cytokines.  More recently, a dual compartment transwell culture system has been 
developed that more closely mimics the intrauterine compartment.  The current 
study compares these two systems with respect to release of pro- and anti-
inflammatory cytokines in response to lipopolysaccharide (LPS), a model 
stimulant.  Tissue samples were exposed to 100 ng/ml LPS for 12 h and 
cytokines were measured by ELISA.  Data are expressed as increase relative to 
non-treated controls.  Levels of interleukin-6 increased in punch culture medium 
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samples (34.2 fold) to a significantly greater extent than in the medium from 
transwell cultures in the amnion (6.6 fold) or choriodecidual (7.1 fold) 
compartments.  Interleukin-8 also showed a significantly greater induction in 
punch (4.8 fold) than transwell amnion (1.6 fold) or choriodecidual (1.7 fold) 
samples.  The anti-inflammatory interleukin-10 showed a significant difference 
between punch (36.5 fold) and transwell amnion (15.4 fold) samples, but no 
difference was observed between punch and transwell choriodecidual (28.5 fold) 
samples.  Neither interleukin-1β nor tumor necrosis factor-α (TNF-α) showed a 
significant difference between the punch and transwell samples. These results 
suggest that methodological factors in gestational membrane culture systems 
can cause differential responses to inflammatory stimuli, confounding 





Cultures of the extraplacental human gestational membranes (amnion, 
chorion and decidua) provide useful in vitro research models for inquiries into 
obstetric challenges such as inflammation, preterm premature rupture of 
membranes (PPROM) and preterm birth.  Gestational membranes collected 
immediately after birth and cultured in vitro allow assessment of responses in 
tissues with an intact cellular matrix.  Such cultures have been used to study 
stimulated production and release of cytokines and prostaglandins in 
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investigations of inflammatory responses of the membranes.1-7  Two model 
systems used extensively to study human gestational membranes in vitro are a 
biopsy punch explant culture system1-4, 6, 8-14 and a transwell mounted explant 
culture system.5, 7, 15-19 
Biopsy punch explants from human gestational membranes have been 
used extensively to study responses of the intact full-thickness membranes 4, 10 
as well as separated amnion 6, 9 or choriodecidua.1, 12  In the punch explant 
culture system, an excised piece of gestational tissue is free-floating in culture 
medium.  This single-compartment system has been used to investigate 
cytokine,1, 3, 4, 6, 8, 9, 13, 14 prostaglandin,1-3, 6, 12-14 adipokine20 and protease3, 10 
regulation.  In contrast, a transwell culture system employs gestational 
membrane explants attached to rigid frames and suspended in culture medium.  
The transwell creates a two-compartment system with discrete amniotic and 
choriodecidual chambers.  The transwell system has been used to study cytokine 
and prostaglandin production induced by bacteria,5, 7, 18, 21 yeast 19 or oxygen 
tension 15 as well as meconium interactions with the gestational membrane.16  
The two-compartment system has provided a model system in which 
investigators can expose and collect media samples from each side of the 
membrane independently.    
To date no reports have directly compared the cytokine responses of 
traditional free-floating biopsy punch explants and transwell mounted explant 
cultures.  The potential for different responses due to model-related restrictions 
suggests a need for further investigation.  Therefore, the aim of this study is to 
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compare floating biopsy punch and transwell mounted explant culture systems 
for lipopolysaccharide (LPS)-induced cytokine responses.      
 
Materials and Methods 
 
Sample collection. 
Human extraplacental gestational membranes were obtained from healthy 
non-laboring women undergoing scheduled caesarean section deliveries at 37-
39 completed weeks gestation at the University of Michigan Women’s Hospital 
Birth Center in Ann Arbor, Michigan.  Exclusion criteria included cigarette 
smoking, prescription of antibiotics in the past two weeks, collagen vascular 
disease, immunocompromised conditions, bacterial vaginosis or clinical 
chorioamnionitis (as noted in the chart or suspected by attending physician), 
cervical cerclage, third trimester bleeding, major maternal medical conditions 
(e.g., chronic renal disease, sarcoidosis, hepatitis, HIV), pre-eclampsia, diabetes, 
multifetal pregnancy, or any other condition which would require the tissue to be 
sent to pathology.  The investigators had no direct interaction with the human 
subjects and the tissues collected would have been otherwise discarded.  
Personal identifiable information was not collected, in compliance with the 
University of Michigan Institutional Review Board requirements.   
Following delivery, placentae with attached membranes were transported 
to the laboratory in warm isotonic phosphate buffered solution (PBS).  Full 
thickness membranes were dissected from the placental disk, allowing a 3-cm 
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margin to prevent sampling from the transitional zone.  A 3-cm margin was also 
maintained around the site of incision.  Laboratory practices followed universal 
safety precautions for handling human tissue (e.g., personnel vaccination for 
hepatitis B and wearing of laboratory safety glasses, gloves, face mask and lab 
coat when handling tissues). 
 
Culture and treatment. 
From each of seven gestational membranes, twelve punch explants and 
eight transwell explants were collected from throughout the membranes.  Under 
sterile conditions, intact membranes were rinsed with isotonic PBS to remove 
adherent blood clots and randomly sampled for 12-mm punches and 3-cm x 3-
cm squares of tissue.  Individual punches were free-floated in 12 well polystyrene 
tissue culture plates (Becton Dickinson, Franklin Lakes, NJ).  Tissue squares 
were mounted on polycarbonate transwell inserts (gift from Corning Inc., Corning, 
NY), attached with elastic latex bands.  Excess tissue extending beyond the band 
was trimmed and the transwell insert was suspended in culture medium (Figure 
4.1.).  Tissues were mounted with the choriodecidua facing the inner chamber 
and the amnion facing the outer chamber, creating two discrete compartments.   
Cultures were acclimated for 24 h in Dulbecco’s Modified Eagle Medium 
(DMEM) (Gibco, Grand Island, NY) supplemented with 100 units/ml penicillin, 
100 ug/ml streptomycin (HyClone, Logan, UT) and 1% fetal bovine serum (FBS) 
(Gibco, Grand Island, NY).  Culture medium was changed after 6 h and 22 h 
during acclimation.  After acclimation, six punch and four transwell cultures were 
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randomly assigned for culture in DMEM or DMEM supplemented with 100 ng/ml 
lipopolysaccharide (LPS; Salmonella typhimurium, ATCC #14028; List Biological 
Laboratories, Inc., Campbell, CA) for 12 h.   Punch explants were exposed in 1 
ml total volume of medium.  In the transwell cultures, the inner chamber medium 
volume was 0.5 ml and the outer chamber volume was 1.5 ml.   
 
Cytokine assessment. 
Concentrations of the cytokines IL-1β, IL-6, IL-8, IL-10 and TNF-α were 
quantified by ELISA using the manufacturer's suggested protocol (Duosets, R&D 
systems, Minneapolis, MN) in the Immunology Core Facility at the University of 
Michigan Cancer Center.  Immunohistochemistry was performed at the University 
of Michigan Research Histology & Immunohistochemistry Laboratory.  Samples 
were fixed in 10% formalin and stored in 70% ethanol until processing.  Each 
sample was paraffin embedded, sectioned and labeled with IL-6 and IL-8 specific 
polyclonal primary antibodies and biotinylated secondary antibodies (Abcam Inc., 
Cambridge, MA).   
 
Data analysis. 
 Data are represented as concentration mean ± SEM for each 
treatment within a culture method.  Because the culture methods used different 
medium volumes, data are also represented as fold-increase over control to 
allow comparison of LPS activation between culture methods (mean±SEM).  
Differences between control and LPS-stimulated groups were analyzed using t-
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tests.  Mann-Whitney rank sum tests were used for data sets that were not 
normally distributed.  Differences between fold increases of the culture methods 
were analyzed using one-way analysis of variance with Student-Newman-Keuls 




Table 4.1. provides the cytokine concentrations in the medium of control 
and LPS-exposed human gestational membranes in biopsy punch and transwell 
cultures.  Non-treated controls showed no differences in basal release of IL-1β, 
IL-6, IL-10 and TNF-α between the amniotic and choriodecidual compartments of 
the transwell cultures. In contrast, IL-8 had greater unstimulated secretion into 
the choriodecidual compartment (236.48±32.46 ng/ml) than into the amniotic 
compartment (154.30±29.15 ng/ml) in untreated controls (p<0.001).  LPS 
induced a significant increase of IL-1β, IL-6, IL-8, IL-10, and TNF-α in the tissue 
punch cultures as well as on each sides of the transwell cultures compared with 
respective controls (p<0.05; Table 4.1.).  
We evaluated five pro- and anti-inflammatory cytokines in this study and 
identified LPS-induced secretion increases of all cytokines tested.  In the punch 
biopsy explant cultures, LPS increased IL-1β 6.9 (±1.4) fold , IL-6 34.2 (±11.7) 
fold, IL-8 4.8 (±1.4) fold, IL-10 36.5 (±6.0) fold, and TNF-α 222.3 (±47.1) fold over 
control explants. In the transwell cultures, LPS increased secretion of IL-1β 10.3 
(±5.6) fold, IL-6 6.6 (±1.8) fold, IL-8 1.6 (±0.1) fold, IL-10 15.4 (±4.5) fold, and 
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TNF-α 258.2 (±115.5) fold on the amniotic side of the membrane and IL-1β 6.4 
(±2.8) fold, IL-6 7.1 (±2.3) fold, IL-8 1.7 (±0.2) fold, IL-10 28.5 (±4.9) fold, and 
TNF-α 254.1 (±105.2) fold on the choriodecidual side of the membrane (Figure 
4.2.).   
By representing LPS induction within a treatment model as a fold increase 
over non-treated control, we allow a comparison between treatment models that 
is not biased by variations in tissue mass or medium volume (Figure 4.2.).  On 
the basis of fold increase over control, LPS-induced secretion of both IL-6 and IL-
8 was greater in the punch culture system than in either compartment of the 
transwell culture system (p<0.05).  Interestingly, IL-10 showed a significantly 
lower fold increase on the amniotic but not the choriodecidual chamber of the 
transwell culture when compared to punch cultures (p=0.015 and p=0.227, 
respectively).  Furthermore, within the transwell culture system, the IL-10 
increase in the amniotic chamber was significantly lower than the IL-10 increase 
in the choriodecidual chamber (p<0.042).  There were no statistically significant 
differences for IL-1β and TNF-α secretion between transwell and punch cultures. 
Immunohistochemical labeling of IL-6 and IL-8 was performed on paraffin 
embedded sections to identify cellular origins of these cytokines within the 
amnion, chorion and decidua.  IL-6 and IL-8 were selected for evaluation due to 
their significant secretion differences between punch cultures and both 
compartments of the transwell cultures.  Figure 4.3. shows representative 
immunohistological sections of control and LPS treated membranes from punch 
and transwell culture systems.  The IL-6 staining was confined to the decidual 
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region and primarily localized to the intercellular space.  No positive staining was 
observed in the dense collagen layer or in the amnion (Figure 4.3.).  Increased 
IL-6 labeling was observed within the chorion and decidua following treatment 
with LPS and the labeling continued to be distributed in the intercellular space.  
Similarly, IL-8 is identified in the chorionic and decidual regions, but is also 
visualized in the sub-epithelial amnion (Figure 4.4.).  Unstimulated punch and 
transwell membranes show IL-8 positive labeling localized intracellularly within 
the cytoplasm of histiocytes.  After stimulation with LPS, intracellular IL-8 can still 
be visualized but in addition intercellular signal is also present in the chorion and 




Cytokines are important protein mediators of cell signaling within the 
human gestational membranes.  Pro-inflammatory cytokine genes are up-
regulated during labor,22, 23 leading to increased cytokine secretion and triggering 
the induction of prostaglandins24 and matrix metalloproteinases25 that stimulate 
uterine contraction,26 cervical dilation27 and the rupture of the gestational 
membranes.28  Elevated IL-1β, IL-6 and TNF-α levels in the amniotic fluid are 
associated with both term29 and preterm30 parturition.    
In vitro cytokine secretion into explant culture medium has been widely 
used as a measure of inflammation for human gestational membranes.1-8  
Published studies have adopted two major model systems, the biopsy punch 
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explant culture system and the transwell mounted explant culture system.  In the 
present study, we compared LPS-stimulated cytokine release for these two 
model systems.  Consistent with previously published reports,4, 7, 8 elevated 
secretion of all cytokines tested (IL-1β, IL-6, IL-8, IL-10 and TNF-α) was 
observed in response to endotoxic lipopolysaccharide stimulation.  Although both 
systems have been widely used, the present report is the first direct comparison 
of the culture systems and demonstrates that the pattern of LPS-stimulated 
cytokine secretion differs between these culture methods. 
 Elevated IL-6 concentrations in the amniotic fluid have been used as a 
marker of membrane inflammation 31 and are associated with preterm labor 32 
and PPROM.33  After stimulation with LPS, the medium concentrations of IL-6 
were five-fold greater in punch cultures when compared to transwell secretion 
into the amniotic or choriodecidual chambers.  The IL-6 media concentrations 
suggest an amplified cytokine response to LPS in the punch cultures, possibly 
due to positive feedback regulation of IL-6. 
Similar to previous reports showing intense IL-6 staining of decidual and 
chorionic trophoblasts,34, 35 the immunohistochemical labeling of IL-6 reported in 
this study was confined to the choriodecidual region, with no positive staining 
observed in the dense collagen layer or in the amnion.  In contrast, this study 
reports IL-6 primarily localized to the intercellular space where others have 
reported intracellular localization.34, 35  Intercellular IL-6 would suggest that high 
levels of IL-6 are rapidly released from choriodecidual cells and diffuse into the 
surrounding tissue.    Previous findings support the choriodecidua as the primary 
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site of IL-6 production in non-laboring membranes, with little or no production in 
the amnion.6, 14  In a series of papers by Simpson et al., separated human 
amnion or choriodecidua from non-laboring deliveries were stimulated using LPS 
(5 ug/ml) and IL-6 secretion was measured by ELISA.  Results showed a 
significant 3 fold increase from the choriodecidual explants and no effect in the 
amniotic explants.   
Interestingly, we observed similar levels of IL-6 in the amniotic and 
choriodecidual media, as reported by Zaga-Clavellina et al. after 24 h of 
stimulation with cervicovaginal derived E. coli.18  Taken together the histological 
data and transwell culture medium concentrations establish the choriodecidua as 
the primary site of IL-6 production.  Cytokines have been previously shown to 
cross the gestational membranes in vitro but at rates much lower than those 
necessary to allow equal choriodecidual and amniotic levels of IL-6 after 12 h of 
stimulation.17  Therefore, we conclude that IL-6 crosses the choriodecidual-
amniotic barrier at rates much greater than previously suggested.       
 Although levels of IL-8 secretion from gestational membranes have not 
been well documented, our LPS-induction appears similar to a previous report.4  
The current study reports a 4.8 (±1.4) fold increase using the punch system, 
similar to the 3.4 fold increases reported previously by Menon et al. after 24-h 
stimulation with 100 ng/ml LPS using a punch explants from intact membranes.4  
The mean IL-8 concentration seen in the present study was nearly three-fold 
greater in punch cultures compared with transwell culture medium in the amniotic 
or choriodecidual chambers.  It should be noted that these modest fold increases 
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represent relatively large changes in release and local concentration due to the 
high unstimulated secretion of IL-8.  The immunohistochemistry provides 
evidence of stimulation in all three layers of membrane, suggesting both amniotic 
and choriodecidual secretion.   
The LPS-induced secretion of IL-10 was 15.4 (±4.5) fold and 28.5 (±4.9) 
fold greater than untreated controls in the transwell amniotic and choriodecidual 
compartments, respectively.  This significant difference is the first report of IL-10 
being directionally secreted from the gestational membranes in vitro.   
IL-10 is an important anti-inflammatory cytokine, inhibiting immune 
function and suppressing pro-inflammatory cytokine production.36  Induced by 
other cytokines and  prostaglandins,36, 37 IL-10 has emerged as a possible 
mediator of pregnancy maintenance.38  Through its anti-inflammatory effects and 
the suppression of the cytokine cascade that leads to prostaglandin and matrix 
metalloproteinase production, Il-10 may prevent gestational membrane rupture 
and maintain quiescence of the myometrium.  Preferential secretion of IL-10 from 
the chorioamniotic face of the gestational membranes suggests the gestational 
membranes may play an important role in maintaining myometrial quiescence 
within the uterus.   
Increased IL-8 concentrations were observed in the choriodecidual 
compartment medium compared to the amniotic compartment medium in 
unstimulated control transwell cultures, suggesting directional secretion of 
cytokines from the human gestational membranes.  The qualitative histological 
findings in this study support the cytokine measurement data, with positive IL-8 
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labeling being observed primarily in the decidual region of the untreated 
transwells.  The ability of IL-8 to cross the gestational membranes as a functional 
protein has yet to be investigated.   
  We suggest that the differences in cytokine response between culture 
systems reflects the lack of compartmentalization in the punch explant system.  
In contrast to the single compartment punch system, the transwell culture system 
maintains separated amniotic and choriodecidual compartments that more 
closely mimics the physiologic separation of fetal and maternal compartments in 
vivo.  Cytokines are regulated through receptor-mediated activation of second 
messenger and nuclear transcription pathways that are susceptible to positive 
feedback.39  Secretion of cytokines into the single-compartment punch system 
may allow direct non-physiologic signaling between the amnion and 
choriodecidua through the shared medium, leading to increased positive 
feedback on both sides of the membrane and causing the rapid cytokine surge 
seen at 12 h.  As such, the amplified response seen in punch explant cultures 
exposed to LPS may not accurately reflect physiologic responses as would occur 
in vivo.  In contrast, the two-compartment transwell culture system prevents 
signaling through the medium between the amnion and the choriodecidua, 
thereby providing a more physiologic in vitro model of cytokine response of 









Figure 4.1.  Transwell explant culture system. Gestational membranes were 
mounted to transwell frames and suspended in 12-well culture plates.  The 
membrane created a barrier maintaining an internal choriodecidual compartment 









 Table 4.1. In vitro Cytokine Secretion into Culture Media by Human Gestational Membranes using a Biopsy Punch 
Explant Culture System or a Transwell Mounted Explant Culture Systema  
 
 
 Punch Transwell Amnion Transwell 
Choriodecidua 
 Control LPSb LPSb LPSbControl Control      
Interleukin-1β  10.66 66.50 30.54 203.10 36.72 126.72 
(pg/ml)  (1.68) (13.87) (10.40) (81.60) (18.91) (42.35) 
        
Interleukin-6 4.42 78.83 15.22 80.34 23.75 104.19 
(ng/ml)  (1.24) (20.27) (5.33) (30.10) (7.33) (23.81) 
        
Interleukin-8 62.41 225.37 154.30c 238.46 236.48c 377.94 
(ng/ml)  (14.23) (48.57) (29.15) (43.81) (32.46) (55.59) 
        
Interleukin-10 12.61 335.11 15.42 166.57 15.34 290.66 
(pg/ml)  (2.78) (50.05) (4.21) (69.59) (4.13) (70.21) 
        
TNF-α 21.37 5026.48 33.11 8394.66 50.04 11109.32 
(pg/ml)  (3.44) (1419.42) (4.31) (4192.91) (13.50) (4789.19) 
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Abbreviations: LPS, lipopolysaccharide; TNF-α, tumor necrosis factor-α. 
a Cytokines were measured 12 h after incubation with or without 100 ng/ml LPS.  Transwell culture cytokine 
concentrations are provided separately for the amniotic and choriodecidual compartments.  Data are presented as mean 
(SEM).  (N= 7 membranes) 
b LPS treatments induced a significant increase of all cytokines from their respective controls (P<0.05).   
c Basal secretion of Interleukin-8 differed significantly between the amniotic and choriodecidual sides of the transwell 
culture (P<0.001).   
 
 





















































































































Figure 4.2.  Lipopolysaccharide (LPS)-induced release of (A) interleukin-6 (IL-6), 
(B) interleukin-8 (IL-8), (C) interleukin-10 (IL-10), (D) interleukin-1β (IL-1β), and 
(E) tumor necrosis factor-α (TNF-α) into culture medium.  Data are represented 
as fold increase over non-treated control samples ± SEM.  Transwell culture 
cytokine increases are provided separately for the amniotic and choriodecidual 
compartments.  * Indicates significant fold-increase difference from punch culture 
(P<0.05). ‡ Indicates significant difference from TW-CD (P<0.05).  TW Amn 
indicates transwell media from amniotic chamber; TW CD indicates transwell 
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Figure 4.3.  Immunohistochemical analysis of Interleukin-6 (IL-6) expression in 
human gestational membranes.  Increased induction of IL-6 by lipopolysacchride 
(LPS) was identified within intercellular regions of the chorion and decidua of 
free-floating punch explants (A) and transwell mounted explants (C), compared 
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Figure 4.4.  Immunohistochemical analysis of Interleukin-8 (IL-8) expression in 
human gestational membranes.  Increased induction of IL-8 by lipopolysacchride 
(LPS) was identified within intercellular regions of the chorion, decidua and sub-
epithelial amnion of free-floating punch explants (A) and transwell mounted 









Evaluation  of PBDE-stimulated release of cytokines from  
human extraplacental membranes 
 
 
Methods and Materials 
 
Sample collection. 
 Sample collection was as described in Chapter IV. 
 
Culture and treatment. 
 Biopsy punch culture methods were as described in Chapter IV.  Human 
amniotic epithelial and fibroblast cells were isolated as described in the Loch-
Caruso Laboratory Standard Operating Procedures with modifications noted. 
Briefly, freshly collected amnion was carefully separated from the 
choriodecidual membranes.  Tissue was rinsed with Dulbecco’s Modified Eagle 
Medium (DMEM) (Gibco, Grand Island, NY) and cut into 2 in2 sections.  Tissue 
was added to 250 ml incubation bottles containing 100 ml DMEM supplemented 
with 100 units/ml penicillin, 100ug/ml streptomycin (Hyclone, Logan, UT), where 
amnion epithelial cells were dissociated at 37°C using 0.125 g trypsin and 0.02 g 
DNAse I for 25 minutes.  Fifty milliliters of dissociation solution was removed and 
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dissociation was repeated.  After the second dissociation, tissues pieces were 
removed and supernatants from first and second dissociations were composited. 
Epithelial cells were isolated from the digested tissue using a 5-20-40-60% 
Percoll (GE Healthcare, Upsalla, Sweden) gradient.   
After trypsin digestion, tissue pieces were transferred to 100 ml DMEM 
supplemented with 100 units/ml penicillin, 100 ug/ml streptomycin and with 10% 
fetal bovine serum (FBS) to inactivate trypsin, rinsed and transferred to a new 
incubation bottle.  To this mixture, 0.100 g collagenase and 0.02 g DNAse I were 
added and incubated for 50 min at 37°C to release amniotic fibroblast cells.  After 
incubation, the remaining tissue was discarded and the released cells were 
pelleted and rinsed.  Resuspended fibroblast cells were then isolated using a 5-
20-40-60% Percoll gradient. 
After isolation, cells were acclimated for 24 h in 100 mm culture plates 
containing DMEM supplemented with 100 units/ml penicillin, 100 ug/ml 
streptomycin and with 10% FBS, before being used in experiments.     
Tissue and cells were treated for 12 or 24 h with DMEM supplemented 
with 100 units/ml penicillin, 100 ug/ml streptomycin and with 10% FBS with or 
without 100 ng/ml lipopolysaccaride (positive control), 0.2% dimethyl sulfoxide 
(DMSO; solvent control), BDE-47, BDE-100 or BDE-153.    
 
Cytokine assessment. 
 Cytokine concentrations of interleukin-1β (IL-1β), interleukin-6 (IL-6) and 





 Data for biopsy punch experiments are represented as mean ± SEM of the 
membrane means for each treatment (N=4-5).  Membrane means were 
calculated by averaging the individual well concentrations for each membrane 
(N=3-4).  Well concentrations were calculated by averaging replicate ELISA 
determinations for each treatment well.   
 Data for isolated primary cell experiments are represented as mean ± 
SEM of the individual membrane fold increase over non-treated solvent control 
(0.2% DMSO) (N=3-5).  For each membrane, individual treatment fold increases 
over solvent control were calculated for each treatment group by dividing the 
mean treatment level by the mean solvent control concentration (N=4).     
 Differences between treatments were tested by analysis of variance with 




Based on the LPS-stimulated cytokine release data described in Chapter 
IV, the biopsy punch explant cultures method was selected for these studies to 
identify the stimulatory effects of PBDEs on this tissue.  Although transwell 
mounted explant culture methods were shown to be more physiologically 
relevant, the amplified effects seen in the Punch culture system were desirable in 
preliminary experiments to identify PBDE–induced effects. 
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The PBDE treatment of punch cultures showed no statistical difference 
from the solvent control for any of the congeners tested.  LPS-induced positive 
control values were significantly elevated in all punch culture experiments.  In 
addition, no difference was observed between the 0.2% DMSO treated solvent 
control and the untreated control. 
 To further evaluate the stimulatory effects of PBDEs on cytokine secretion, 
isolated amniotic epithelial or fibroblast cells were treated with BDEs-47, 100 and 
153.  This replicated previous work in the lab that showed a positive increase in 
cytokine secretion in response to PBDE stimulation (Dr. K. Brant, unpublished 
data).   
 The PBDE treatment of neither amnion epithelial nor amnion fibroblast 
cells resulted in a significant increase in IL-6 secretion into the surrounding 



























Figure A.1.  PBDE-stimulated interleukin-6 (Il-6) secretion into culture media by 
human gestational membranes biopsy punch explants. Il-6 was measured after a 
12-h incubation with untreated medium, 0.2% dimethyl sulfoxide (DMSO; solvent 
control), lipopolysaccharide (LPS; positive control), 60 uM BDE-47 or 60 uM 
BDE153.  IL-6 was measured by enzyme-linked immunosorbent assay (ELISA).  


































Figure A.2.  PBDE-stimulated interleukin-8 (Il-8) secretion into culture media by 
human gestational membranes biopsy punch explants. Il-8 was measured after a 
12-h incubation with untreated medium, 0.2% dimethyl sulfoxide (DMSO; solvent 
control), lipopolysaccharide (LPS; positive control), 60 uM BDE-47 or 60 uM 
BDE153.  IL-8 was measured by enzyme-linked immunosorbent assay (ELISA).  



























Figure A.3.  PBDE-stimulated interleukin-1β (Il-1β) secretion into culture media 
by human gestational membranes biopsy punch explants.  Il-1β was measured 
after a 12-h incubation with untreated medium, 0.2% dimethyl sulfoxide (DMSO; 
solvent control), lipopolysaccharide (LPS; positive control), 60 uM BDE-47 or 60 
uM BDE153.  IL-1β was measured by enzyme-linked immunosorbent assay 
(ELISA).  Bars represent mean ± SEM.  N=4 membranes; 3-4 








































Figure A.4.  PBDE-stimulated interleukin-6 (Il-6) secretion into culture media by 
primary amniotic epithelial cell isolates.  Il-6 was measured after a 24-h 
incubation with 0.2% dimethyl sulfoxide (DMSO; solvent control), BDE-47 (10 
uM, 60 uM), BDE 100 (10 uM, 60 uM) or BDE153 (10 uM, 60 uM).  IL-6 was 
measured by enzyme-linked immunosorbent assay (ELISA).  Bars represent the 
mean ± SEM of the fold increases over solvent control within each experiment.  
Lipopolysaccharide (LPS) positive control induced a significant increase in IL-6 








































Figure A.5.  PBDE-stimulated interleukin-6 (Il-6) secretion into culture media by 
primary amniotic fibroblast cell isolates.  Il-6 was measured after a 24-h 
incubation with 0.2% dimethyl sulfoxide (DMSO; solvent control), BDE-47 (10 
uM, 60 uM), BDE 100 (10 uM, 60 uM) or BDE153 (10 uM, 60 uM).  IL-6 was 
measured by enzyme-linked immunosorbent assay (ELISA).  Bars represent the 
mean ± SEM of the fold increases over solvent control within each experiment. 
Lipopolysaccharide (LPS) positive control induced a significant increase in IL-6 
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 PBDE abundances in human tissue and fluids from the United States are 
among the highest in the world (reviewed by Frederiksen).1  Further, these levels 
seem to be continuously rising in the United States while PBDE levels in other 
parts of the world are remaining static or decreasing.2-4  PBDEs raise significant 
health and regulatory concerns due to persistence, bioaccumulation and 
developmental toxicities of PBDEs (reviewed by the Institute of Medicine of the 
National Academies).5  Perinatal exposure to PBDEs is of particular concern due 
to reports of higher PBDE abundances in neonatal infants than in adults, and a 
lack of reports for prenatal infants.6-9       
Scientific research has established that human gestational membranes 
have significant roles in the timing of birth through the production of cytokines 
and prostaglandins.  Therefore, investigations into the impact of toxicants on the 
human gestational membranes and their role in preterm birth and PPROM are 
warranted.  The research contained in this dissertation is the first to show 
bioaccumulation of PBDEs in the human gestational membranes, identify a 
potential route of gestational membrane exposure through the amniotic fluid and 
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compare culture methods for the investigation of gestational membrane 
inflammatory response in vitro. 
 Total burdens of PBDEs in the human gestational membranes of women 
in Southeast Michigan were 3.3-8.8 fold greater than levels previously reported 
for placental disk samples collected in Denmark, Finland or Spain,10-13 but 
considerably less than fetal liver samples and maternal or fetal sera samples 
from the United States.14-18  Although most studies monitor 5-10 PBDE 
congeners, the present study assessed 21 congeners in the human gestational 
membranes.  This 21-congener study is one of the most inclusive biomonitoring 
reports of PBDE congener profiles in humans.  By analyzing a broad range of 
congeners, I identified BDE-49 as a major constituent of the total PBDE levels in 
this population, comprising 17% of the total PBDE loading.  This was the first 
report of BDE-49 in the human reproductive compartment.  This latter finding 
suggests that other studies that do not measure BDE-49 could be significantly 
underestimating the total PBDE accumulation.    
 Very little is known about the distribution of persistent organic pollutants 
within the human gestational compartment.  In order to identify the sources of 
PBDE exposure for gestational membranes, I evaluated congener-specific 
abundances within the amniotic fluid and gestational membranes.  Gestational 
membranes are supplied with blood from the spiral arteries of the uterus.  These 
arteries are part of the maternal circulation and provide a direct route of PBDE 
exposure to the decidual face of the gestational membranes.  Because the 
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gestational membranes encapsulate the amniotic fluid there is also potential for 
direct transfer of PBDEs across the amnion-amniotic fluid boundary.   
The amniotic fluid levels of PBDEs were much higher than gestational 
membrane levels on a tissue/fluid basis (amniotic fluid- 3.8 ng/ml; gestational 
membrane- 17.4 pg/g) and also on a lipid basis (amniotic fluid- 404 ng/ml; 
gestational membrane- 5.6 ng/g).  Our understanding of the causes for this 
difference is limited because this is the first report of PBDE levels in either of 
these matrices.  Further studies are needed to determine whether PBDEs are 
accumulating in the amniotic fluid over time or if they are mobilized and 
incorporated into the amniotic fluid as it is formed.   
Although the gestational membrane and amniotic fluid PBDE 
concentrations reported here were both from samples collected at the University 
of Michigan Women’s Hospital, limitations in sample collection prevented the 
direct comparison of gestational membrane and amniotic fluid levels using paired 
samples.  The amniotic fluid samples were collected from clinical amniocentesis 
samples, and likely represent an older sample population.  Because some 
PBDEs accumulate over time, an individual’s age can influence the total tissue 
burden.     Further, I did not collect demographic information from either sampling 
group, preventing the identification of other potential confounding factors such as 
body mass index, socioeconomic status, occupational or behavioral exposures, 
number of previous pregnancies and gestational age at time of sampling.   
In addition to the greater total PBDE abundances observed in the amniotic 
fluid compared to gestational membranes, we also saw a strikingly different 
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congener profile between these compartments.  The gestational membranes 
were dominated by small tetra- and penta-BDE congeners, accounting for >80% 
of the total PBDE loading, and had no hepta- through deca- congeners.  In 
contrast, tetra- and penta- congeners accounted for only 18% of the total loading 
in amniotic fluid and octa- through deca- congeners contributed over half of the 
total PBDEs.  These tissue compartment differences in PBDE profiles suggest 
preferential accumulation of specific congeners in the various matrices, possibly 
due to steric exclusion of larger PBDE congeners from the dense gestational 
membranes.  Because these studies are from the same sampling population but 
not from the same women, future studies using paired samples and toxicokinetic 
modeling will be necessary to establish preferential accumulation of PBDEs in 
various reproductive compartments.  Development of a toxicokinetic model of 
PBDE congener distributions in utero gains additional importance because lower 
brominated congeners with eight or fewer bromine atoms have been shown to 
have greater developmental toxicities than higher brominated congeners.5   
Several studies have investigated PBDE concentrations in paired maternal 
and fetal sera samples.17-19  Most such studies observed strikingly similar 
concentrations for maternal and fetal sera samples, suggesting that PBDEs pass 
freely from maternal to fetal circulation through the placenta.  A recent study by 
Doucet et al. investigating the relationship of paired placenta and fetal liver 
samples further supports passage of PBDEs through the placenta to the fetus.20  
However, Doucet et al. found no correlation between placental PBDE levels and 
the much higher fetal liver levels taken from mid-gestation abortus material in 
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North America between 1998 and 2006.  This latter finding suggests the fetal 
liver continuously accumulates PBDEs from the fetal circulation, whereas the 
placenta is allowing PBDEs to pass.   
My research suggests that maternal-fetal blood transfer at the placenta 
may not be the only route of PBDE exposure for the fetus, but that amniotic fluid 
provides a second route of exposure for the fetus.  Amniotic fluid accumulates 
within the confines of the gestational membranes primarily during the second 
trimester.  The total volume of fluid increases from about 200 ml at 16 weeks 
gestation to 1000 ml at 28 weeks gestation.21  This increase in fluid is almost 
entirely of maternal origin, and may contain toxicants mobilized from maternal 
body burdens.  Throughout gestation, the fetus is continuously swallowing and 
“inhaling” amniotic fluid.  Intake into the gastrointestinal and respiratory tracks 
along with dermal exposure provide direct routes of transport into the fetus for 
toxicants that enter the amniotic compartment.  Because it surrounds the fetus 
during gestation, amniotic fluid is possibly highly correlated to the PBDE 
exposure to the fetus.  The high amniotic fluid levels seen in this study provide 
evidence that this route of exposure is significant and warrants further 
investigation.   
 The present study shows that BDE-209 is present in 80% of human 
amniotic fluid samples at concentrations up to 1286 pg/ml fluid.  Because BDE-
209 has a short biological half-life (15 days),22  the latter finding is an indication of 
continuous exposure to BDE-209.  Furthermore, the presence of BDE-209 
provides an explanation for the high levels of nona-BDE congeners observed in 
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amniotic fluid.  Previous studies showed that BDE-209 is metabolized to nona-
BDE congeners in fish and birds.23-25  Because nona-BDEs are not commercially 
produced for use as flame retardants, it is plausible that the high levels of nona-
BDEs seen in this study are a result of deca-BDE breakdown rather than direct 
environmental exposure to nona-BDEs.    
Biomonitoring studies often report biological loading of lipophillic 
contaminants in units of weight per gram lipid within a given tissue.  This metric 
provides a standardized base for describing the chemical kinetics within an 
organism and a standard by which to compare between organisms or between 
geographic regions.  Although this practice is useful for assessing chemical 
dynamics and accumulation patterns, from a toxicological standpoint it is more 
useful to examine tissue contamination data as weight per gram tissue.  The 
measured concentration of a chemical within the tissue more directly reflects the 
toxicant dose within an organism or tissue.  Therefore the results reported in this 
dissertation have been described primarily on a weight per gram tissue basis, 
with secondary reference to lipid content within the gestational compartments 
and concentrations on a lipid weight basis.   
   Although the PBDE biomonitoring data are reported on a weight per 
gram tissue basis to provide biological significance to the findings, it may also be 
of interest to consider these data on a mole weight per gram tissue basis when 
comparing between PBDE congeners.  Because of the high atomic weight of 
bromine (a.w. = 79.904 gram/mol), PBDE congeners have widely variable 
molecular weights.  For example the formula weights of the PBDEs measured in 
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these studies range from 406.90 g/mol for BDE-17 to 959.17 g/mol for BDE-209.  
Therefore, for a given weight per gram tissue concentration of PBDEs there 
would be more than twice as many molecules of BDE-17 then there would be of 
BDE-209.  From a toxicological standpoint, the number of molecules available to 
interact with receptors or target proteins within a given tissue may be of more 
importance than the total weight of the molecules.   
  To identify the most appropriate model system for evaluating PBDE-
stimulated cytokine release from the extra-placental gestational membranes, I 
conducted a comparative assessment of the two primary explant culture 
systems; free-floating biopsy punch explant cultures and transwell-mounted 
explant cultures.  To make this comparison I used lipopolysaccharide (LPS) as a 
model stimulant because it has been well established as a modulator of cytokine 
secretion in the scientific literature of both culture systems.  This study showed 
significantly increased effects for several cytokines using the biopsy punch 
explant culture system compared to the transwell explant culture system.  The 
increased cytokine response in the punch cultures suggest an amplification of 
cytokine signaling through non-physiologic signaling between opposing faces of 
the membrane.  Based on these findings, future investigations should select 
carefully the model system that most appropriately meets the needs of the 
research.  
This work did not show a stimulatory effect for BDE-47 or BDE-153 using 
the biopsy punch explant system (Chapter 5: Appendix A).  Furthermore, I was 
unable to show a significant increase in pro-inflammatory cytokine release in 
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response to BDE- 47, 100 or 153 exposure in isolated amniotic cells.   
 The absence of an effect seen in the PBDE treatment studies does not 
provide conclusive evidence that PBDEs do not induce a pro-inflammatory 
cytokine response in this tissue.  These experiments evaluated only a select 
group of cytokines exposed to only two congeners, at a single time point.  Being 
a lipophillic compound,6 the concentration of PBDEs reaching the site of action is 
difficult to quantify in the in vitro culture systems due to adsorption to the culture 
wells.26  In addition to the mechanistic and toxicological studies currently being 
undertaken in this laboratory and others, the broad range of sites for potential 
immunomodulation suggests a microarray screen of gene modulation is 
warranted for these chemicals.     
It is also plausible that if PBDEs do not directly induce an increase in pro-
inflammatory cytokines, they may act collaboratively with infectious agents to 
cause gestational membrane inflammation and adverse birth outcomes.  
Recently, Lundgren et al. showed that in vivo PBDE exposure resulted in marked 
decreases or complete absence of select pro-inflammatory cytokines using a 
murine model exposed to a coxsackie B3 infection.27  Equally noteworthy, the 
inhibition of cytokines due to PBDE exposure was also seen in uninfected control 
animals.  PBDE accumulation within the gestational membranes may provide a 
selective block in immune signaling pathways, allowing the proliferation of 
ascending vaginal bacteria within immunocompromized gestational membranes.  
The research contained in this dissertation has addressed the questions of 
PBDE accumulation in the human gestational membranes and amniotic fluid.  In 
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addition, it has compared in vitro model systems used to identify cytokine 
stimulation and used them to evaluate several PBDE congeners.  But in the end 
it has generated more questions than it has answered.  This work provides a 
basis for future investigations into the compartmental dynamics and 
toxicokinetics of PBDEs within the human gestational compartment.  Based on 
the PBDE profiles in the gestational membranes and amniotic fluid it is likely that 
all PBDE congeners do not partition proportionately between tissues and fluids.  
This implies a yet-to-be-developed model for selective accumulation of more 
toxic congeners within a single tissue.  This work also provides a basis for future 
investigations of PBDE interactions within human gestational membranes.  By 
establishing that PBDEs accumulate within the human gestational membranes, I 
have placed them within a tissue that is known to mediate birth outcomes.  
Interactions with other persistent organic pollutants, infectious agents and 
signaling cascades still need to be addressed.  Finally, my comparison of in vitro 
explant model systems for evaluating cytokine release has spawned questions 
regarding the physiologic relevance of the punch culture system.  Identified 
differences between the punch and transwell culture systems may prevent the 
direct comparison of studies using these two culture methods for studying 
cytokine release. 
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